Bibliography
- Borden EC, Amato DA, Rosenbaum C, Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987;5:840-50
- van Oosterom AT, Mouridsen HT, Nielsen OS, Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-406
- Buesa JM, Mouridsen HT, van Oosterom AT, High-dose DTIC in advanced sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-9
- Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006;18:615-21
- Wilhelm SM, Carter C, Tang LY, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
- Rahmani M, Davis EM, Bauer C, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of MCL-1 through inhibition of translation. J Biol Chem 2005;280:35217-27
- Escudier B, Eisen T, Stadler WM, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
- Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;24(359):378-90
- Gupta-Abramson V, Troxel AB, Nellore A, Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
- Ambrosini G, Cheema HS, Seelman S. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2008;Apr7(4):890-6
- Peng CL, Guo W, Ji T, Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 2009;8(18):1729-36
- Strumberg D, Richly H, Hilger RA. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
- Maki RG, D'Adamo DR, Keohan ML. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;Jul127(19):3133-40
- McDermott DF, Sosman JA, Gonzalez R, Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;126(13):2178-85
- Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
- Maruwge W, D'Arcy P, Folin A. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther 2008;11:67-78
- von Mehren M, Rankin C, Goldblum JR, Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012;1118(3):770-6
- Bertuzzi A, Stroppa EM, Secondino S. Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy [abstract No:10025]. 2010 ASCO Annual Meeting
- Pacey S, Ratain MJ, Flaherty KT, Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2011;29(3):481-8
- ClinicalTrials.gov Identifier: NCT00837148. Available from: www.clinicaltrials.gov [Last access 18 June 2011]
- D'Adamo DR, Keohan ML, Carvajal RD, A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST) [abstract No:10025]. 2011 ASCO Annual Meeting; 3 - 7 2011; Illinois, Chicago
- Zucali PA, Bertuzzi A, Parra HJ, The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs 2008;26(2):175-81
- García-Del-Muro X, López-Pousa A, Maurel J, Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;2029(18):2528-33